PF-05175157

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII P826WR56FI

Structure

InChI Key BDXXSFOJPYSYOC-UHFFFAOYSA-N
Smiles Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1
InChI
InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H27N5O2
Molecular Weight 405.5
AlogP 3.7
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 83.88
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
Acetyl-CoA carboxylase inhibitor INHIBITOR PubMed Other
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Ligase
- 33-45 - - -
Enzyme
- 27-98 - - -
Assay Description Organism Bioactivity Reference
Inhibition of human recombinant ACC1 after 1 hr by transcreener assay Homo sapiens 98.0 nM
Inhibition of human recombinant ACC2 after 1 hr by transcreener assay Homo sapiens 45.0 nM
Inhibition of human recombinant ACC1 assessed as incorporation of [14C]bicarbonate into [14C]malonyl-CoA by radiometric assay Homo sapiens 27.0 nM
Inhibition of human recombinant ACC2 assessed as incorporation of [14C]bicarbonate into [14C]malonyl-CoA by radiometric assay Homo sapiens 33.0 nM
Inhibition of rat recombinant ACC1 assessed as incorporation of [14C]bicarbonate into [14C]malonyl-CoA by radiometric assay Rattus norvegicus 23.5 nM
Inhibition of rat recombinant ACC2 assessed as incorporation of [14C]bicarbonate into [14C]malonyl-CoA by radiometric assay Rattus norvegicus 50.4 nM
Inhibition of malonyl-CoA formation in Wistar rat hepatocytes after 5 hrs by mass spectrometry Rattus norvegicus 29.9 nM
Inhibition of malonyl-CoA production in Sprague-Dawley rat quadriceps assessed as unbound plasma drug concentration at 5 ml/kg, po after 1 hr by LC/MS analysis Rattus norvegicus 870.0 nM
Inhibition of malonyl-CoA production in Sprague-Dawley rat liver assessed as unbound plasma drug concentration at 5 ml/kg, po after 1 hr by LC/MS analysis Rattus norvegicus 540.0 nM
Inhibition of hepatic DNL in po dosed Sprague-Dawley rat assessed as inhibition of incorporation of [14C]acetate into [14C]lipid administered 1 hr prior to [14C]acetate challenge measured after 1 hr Rattus norvegicus 82.0 %
Inhibition of hepatic DNL in po dosed Sprague-Dawley rat assessed as unbound plasma drug concentration administered 1 hr prior to [14C]acetate challenge measured after 1 hr Rattus norvegicus 326.0 nM
Reduction of respiratory exchange ratio in Sprague-Dawley rat assessed as unbound plasma drug concentration measured at 1 mg/kg to 100 mg/kg, po after 120 mins Rattus norvegicus 119.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 6.34 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 6.93 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 6.93 %

Cross References

Resources Reference
ChEMBL CHEMBL3359265
DrugBank DB12096
FDA SRS P826WR56FI
PubChem 52934180
SureChEMBL SCHEMBL1892015
ZINC ZINC000117445039
CONTENTS